卡波扎尼布
肝细胞癌
医学
肿瘤科
癌症研究
免疫疗法
内科学
靶向治疗
贝伐单抗
癌症
化疗
作者
Makoto Yamamoto,Toshio Terashima,Tatsuya Yamashita,Akihiro Seki,Hidetoshi Nakagawa,Kouki Nio,Tetsuro Shimakami,Hajime Takatori,Kuniaki Arai,Eishiro Mizukoshi,Masao Honda,Shinji Takeuchi,Taro Yamashita
摘要
Abstract A 72‐year‐old man with metastatic hepatocellular carcinoma previously received first‐line systemic therapy with atezolizumab plus bevacizumab. His disease was judged to be progressing 5 months after treatment initiation. Comprehensive genomic profiling revealed cytoplasmic mesenchymal–epithelial transition factor amplification. On the basis of an expert panel's recommendation, he received cabozantinib as second‐line therapy. The tumors shrank markedly and continued to shrink 6 months after treatment. Comprehensive genomic profiling could provide useful information for selecting effective second‐line treatments for patients with hepatocellular carcinoma after first‐line immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI